MedTrace Logo

The Brain Metabolic Change in Chronic Cancer Pain Patient: FDG PET Image Study

NCT04255628 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-09-21

No results posted yet for this study

Summary

Cancer pain deteriorated in quality of life and related with numerous psychosocial problems. Over the one third of cancer patient suffered from moderate to severe cancer pain, even under adequate pain management.

The 18F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) images can provide quantitative results in clinical oncology. As a functional neuroimaging, the PET evidently provided anatomical activated regions, size, and spatial extent information. In this study, we use FDG-PET to investigate changes concerning the glucose metabolism in the brain with or without cancer pain. Therefore, we may provide useful information to treatment target in cancer pain patients.

Conditions

  • Cancer Pain

Interventions

DIAGNOSTIC_TEST

FDG PET

Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-02
Primary Completion
2022-03-28
Completion
2022-12-29

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04255628 on ClinicalTrials.gov